Advanced search
1 file | 204.42 KB

Similar efficacy and toxicity profile for Idarubicine and Mitoxantrone in induction and intensification treatment of children with acute myeloid leukemia (AML) or myelodysplasia (MDS): long-term results of the EORTC-CLG randomized phase III trial 58921

Author
Organization

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 204.42 KB

Citation

Please use this url to cite or link to this publication:

Chicago
De Moerloose, Barbara, Stefan Suciu, Martine Munzer, Caroline Piette, Karima Yakouben, Genevieve Margueritte, Patrick Lutz, et al. 2011. “Similar Efficacy and Toxicity Profile for Idarubicine and Mitoxantrone in Induction and Intensification Treatment of Children with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS): Long-term Results of the EORTC-CLG Randomized Phase III Trial 58921.” In 53rd ASH Annual Meeting and Exposition : Abstracts, Program and Personal Scheduler. American Society of Hematology (ASH).
APA
De Moerloose, B., Suciu, S., Munzer, M., Piette, C., Yakouben, K., Margueritte, G., Lutz, P., et al. (2011). Similar efficacy and toxicity profile for Idarubicine and Mitoxantrone in induction and intensification treatment of children with acute myeloid leukemia (AML) or myelodysplasia (MDS): long-term results of the EORTC-CLG randomized phase III trial 58921. 53rd ASH annual meeting and exposition : abstracts, program and personal scheduler. Presented at the 53rd Annual meeting of the American Society of Hematology, American Society of Hematology (ASH).
Vancouver
1.
De Moerloose B, Suciu S, Munzer M, Piette C, Yakouben K, Margueritte G, et al. Similar efficacy and toxicity profile for Idarubicine and Mitoxantrone in induction and intensification treatment of children with acute myeloid leukemia (AML) or myelodysplasia (MDS): long-term results of the EORTC-CLG randomized phase III trial 58921. 53rd ASH annual meeting and exposition : abstracts, program and personal scheduler. American Society of Hematology (ASH); 2011.
MLA
De Moerloose, Barbara, Stefan Suciu, Martine Munzer, et al. “Similar Efficacy and Toxicity Profile for Idarubicine and Mitoxantrone in Induction and Intensification Treatment of Children with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS): Long-term Results of the EORTC-CLG Randomized Phase III Trial 58921.” 53rd ASH Annual Meeting and Exposition : Abstracts, Program and Personal Scheduler. American Society of Hematology (ASH), 2011. Print.
@inproceedings{2007966,
  articleno    = {abstract 2615},
  author       = {De Moerloose, Barbara and Suciu, Stefan and Munzer, Martine and Piette, Caroline and Yakouben, Karima and Margueritte, Genevieve and Lutz, Patrick and Uyttebroeck, Anne and Rohrlich, Pierre and Ferster, Alina and Boutard, Patrick and Dresse, Marie-Fran\c{c}oise and Rialland, Xavier and Norton, Lucillia and Sirvent, Nicolas and Karrasch, Matthias and Benoit, Yves and Bertrand, Yves},
  booktitle    = {53rd ASH annual meeting and exposition : abstracts, program and personal scheduler},
  language     = {eng},
  location     = {San Diego, CA, USA},
  publisher    = {American Society of Hematology (ASH)},
  title        = {Similar efficacy and toxicity profile for Idarubicine and Mitoxantrone in induction and intensification treatment of children with acute myeloid leukemia (AML) or myelodysplasia (MDS): long-term results of the EORTC-CLG randomized phase III trial 58921},
  url          = {http://ash.confex.com/ash/2011/webprogram/Paper41962.html},
  year         = {2011},
}